Dosing Starts in SELECT-HD Trial That Seeks to Lower mHTT Levels

Dosing Starts in SELECT-HD Trial That Seeks to Lower mHTT Levels

307465

Dosing Starts in SELECT-HD Trial That Seeks to Lower mHTT Levels

A Phase 1/2 trial evaluating Wave Life Science’s investigational therapy WVE-003 for Huntington’s disease has started dosing patients, the company has announced. The SELECT-HD trial (NCT05032196), underway in clinical sites in Australia, Germany, Poland, and the U.K., is currently looking to enroll 36 Huntington’s patients, ages 25 to 60, at the early stages of the disease and with a specific single nucleotide polymorphism (SNP), called SNP3, in the mutated HTT gene. An SNP is a…

You must be logged in to read/download the full post.